Cytek Biosciences, Inc. (CTKB) came out with a quarterly loss of $0.01 per share versus the Zacks Consensus Estimate of $0.01. This compares to earnings of $0.01 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -200.00%. A quarter ago, it was expected that this company would post a loss of $0.02 per share when it actually produced earnings of $0.01, delivering a surprise of +150%.Over the last four quarters, the company has sur ...

Cytek Biosciences (NasdaqGS:CTKB) Q3 2025 Earnings Call November 05, 2025 04:30 PM ET Speaker0Good day, everyone, and thank you for standing by. My name is RG, and I will be your conference operator today. At this time, I would like to welcome everyone to the Cytek Biosciences Third Quarter 2025 earnings conference call. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question-and-answer session. If you would like to ask a question during this ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _______________________________________________________ FORM 10-Q _______________________________________________________ (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Numbe ...

Exhibit 99.1 Cytek Biosciences Reports Third Quarter 2025 Financial Results FREMONT, Calif., November 5, 2025 (GLOBE NEWSWIRE) – Cytek® Biosciences, Inc. ("Cytek Biosciences" or "Cytek") (Nasdaq: CTKB), a leading cell analysis solutions company, today reported financial results for the third quarter ended September 30, 2025. Recent Highlights "Our third quarter results are encouraging and demonstrate the strength of our established brand and technology and our market leadership position," said Wenbin Jiang, ...

FREMONT, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Cytek® Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), a leading cell analysis solutions company, today reported financial results for the third quarter ended September 30, 2025. Recent Highlights Total revenue for the third quarter of 2025 was $52.3 million, representing a 2% increase compared to the third quarter of 2024Expanded to a total installed base of 3,456 Cytek instruments, adding 161 units in the third quarter of 2025Double-dig ...

FREMONT, Calif., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Amid the reduction of various government grant programs and global economic challenges that have tightened research funding, Cytek Biosciences, Inc. (Nasdaq: CTKB) is taking steps to ensure critical scientific research can continue. Joining the International Society for Advancement of Cytometry’s (ISAC) mission to advance global availability and adoption of cytometry technology and empower scientists, Cytek has launched a two-part research support initiativ ...

FREMONT, Calif., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), today announced it will report financial results for the third quarter 2025 after market close on Wednesday, November 5, 2025. The company’s management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its results, business developments and outlook. Live audio of the webcast will be available on the “Investors” section ...

Cytek European Facility Cytek’s new facility in Amsterdam, The Netherlands, expands the company’s capacity to meet the growing demand for comprehensive cell analysis solutions. FREMONT, Calif., Oct. 15, 2025 (GLOBE NEWSWIRE) -- In a move that strengthens its European operations and enhances service for its customers, spectral flow cytometry leader Cytek Biosciences, Inc. (Nasdaq: CTKB) today announced the relocation of its European headquarters to a new facility in Amsterdam’s Life Sciences District. Th ...

公司技术与行业地位 - 公司作为光谱流式细胞术领域的先驱，将展示其先进的高参数解决方案，以满足癌症研究和诊断对更深入、更快速细胞洞察的需求 [1] - 公司的全光谱分析技术区别于传统流式细胞术，深刻改变了细胞生物学、免疫学、肿瘤学和靶向治疗方法的认知，带来简化的工作流程、加速的发现和提升的效率 [2] - 公司的全光谱分析系统已成为全球研究人员的首选光谱技术，有超过2800篇经同行评审的出版物引用了其使用 [2] - 公司的光谱技术能够在单管中分析超过40种标志物，显著提高效率并减少分析时间，无需多管检测板，节省试剂并简化工作流程 [7] 行业会议参与与展示 - 公司将在本月晚些时候的两个重要行业活动中展示其解决方案：2025年欧洲临床细胞分析学会会议和第四十届国际临床细胞计量学会年会暨课程 [1] - 在ESCCA 2025会议上，公司将展示其全面的端到端细胞分析解决方案，旨在为临床医生和研究人员提供更深入的科学见解，实现更快的数据驱动决策 [4] - 在ESCCA会议上，一位血液病理学专家将主持题为“结合光谱流式细胞术和基于机器学习的决策支持系统以精准诊断白血病和淋巴瘤”的研讨会 [4] - 在ICCS 2025年会上，另一位教授将主持相同的关于结合光谱流式细胞术与机器学习进行白血病和淋巴瘤精准诊断的研讨会 [6] 公司产品平台与业务 - 公司是一家领先的细胞分析解决方案公司，通过其专利全光谱分析技术提供高分辨率、高内涵和高灵敏度的细胞分析工具 [8] - 公司平台包括核心全光谱分析仪器、试剂鸡尾酒制备系统、增强型小颗粒检测技术、流式细胞仪和成像产品以及试剂、软件和服务，提供全面的集成解决方案 [8]

会议背景 - 摩根士丹利全球医疗保健会议第三天举行 由生命科学工具团队研究助理Edmund Tu主持[1] - Cytek Biosciences公司首席执行官Wenbin Jiang和首席财务官Bill McCombe代表公司出席会议[1] 参会人员 - 摩根士丹利方由研究助理Edmund Tu作为会议主持人[1] - Cytek Biosciences公司方由首席执行官Wenbin Jiang和首席财务官Bill McCombe作为代表出席[1] 信息披露 - 摩根士丹利要求参会者查阅公司研究披露网站morganstanley.com/researchdisclosures获取重要披露信息[2] - 参会者可通过销售代表渠道咨询相关问题[2]